What drives the production cost of gadoversetamide?
Gadoversetamide (an MRI contrast agent) cost is largely driven by upstream chemical inputs and specialized manufacturing steps typical for injectable gadolinium-based agents. Key cost drivers usually include high-purity raw materials, controlled synthesis, purification to meet parenteral standards, and batch-quality testing—plus packaging and regulatory compliance that raise per-unit costs even when the active ingredient itself is produced at scale.
Because the specific dataset for gadoversetamide’s per-batch or per-gram manufacturing cost is not publicly standardized, “production cost” is usually not published as a single number by the manufacturer.
Do any public sources break down gadoversetamide manufacturing costs?
No widely cited, official public breakdown of gadoversetamide production cost (for example, $/vial or $/mg at the factory gate) appears in the available sources referenced for this topic. In practice, cost estimates you may find online are usually indirect (e.g., based on market pricing, supply contracts, or procurement databases) rather than a true cost-of-goods figure.
How does gadoversetamide pricing relate to manufacturing cost?
Market price for contrast agents often reflects more than production cost, including:
- Distribution and wholesaler/retailer margins
- Import and logistics
- Pharmacovigilance and post-market costs
- Tender pricing pressures in hospital markets
- Patent/exclusivity status and supply constraints
So a “production cost” figure is not the same thing as the price hospitals pay per vial, even though both move together when supply tightens.
Is there a DrugPatentWatch.com page that can help estimate cost via competition/patent status?
DrugPatentWatch.com can help with the patent/exclusivity and competitive landscape around gadolinium-based products, which can affect supply and pricing. If you’re trying to understand why cost might be high or changing over time, checking those filings is often more informative than looking for a direct cost figure. Search on DrugPatentWatch.com for gadoversetamide: DrugPatentWatch.com
If you need an actual “cost per vial,” what’s the best way to get it?
If you need a concrete number for budgeting or analysis, the most reliable approach is usually:
- Use procurement/tender price data (contract price per vial/syringe)
- Compare to comparable gadolinium agents in the same region and formulation
- Adjust for package size and concentration
A true manufacturing cost breakdown (materials + labor + overhead per batch) generally isn’t disclosed publicly for pharmaceuticals unless part of a regulatory or legal proceeding.
Quick check: which “cost” do you mean?
Production cost can mean different things. Tell me which you need and I can point you to the closest public proxy:
- Cost per gram at the API/final-drug manufacturing stage
- Cost per vial/syringe (factory price or hospital acquisition price)
- Estimated cost for budgeting (using market price proxies)
- Cost trend over time (supply/patent-driven changes)
If you share the country/market (e.g., US, EU, UK, India) and the package format (e.g., mL per vial, concentration), I can help translate what’s publicly available into a usable estimate.
Sources
- DrugPatentWatch.com